Deerfield Mgmt, LP revealed that they own a 4.2% stake in Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) in a Schedule 13G disclosure that was filed with the SEC on Friday, September 30th. The investor owns 783,375 shares of the stock worth approximately $4,896,094. The reporting parties listed on the disclosure included Deerfield Mgmt, LP, Deerfield Management Company, LP, Deerfield Special Situations Fund, LP and James E Flynn. The disclosure is available through the SEC website at this link.
Separately, Sphera Funds Management LTD. boosted its position in Catabasis Pharmaceuticls by 184.9% in the first quarter. Sphera Funds Management LTD. now owns 230,041 shares of the company’s stock valued at $1,159,000 after buying an additional 149,299 shares during the last quarter. Hedge funds and other institutional investors own 66.58% of the company’s stock.
Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) opened at 6.25 on Friday. Catabasis Pharmaceuticls Inc. has a 12 month low of $3.31 and a 12 month high of $10.83. The company has a 50-day moving average of $4.69 and a 200 day moving average of $4.78. The stock’s market capitalization is $96.13 million.
Catabasis Pharmaceuticls (NASDAQ:CATB) last issued its earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.04. On average, equities research analysts anticipate that Catabasis Pharmaceuticls Inc. will post ($2.47) earnings per share for the current fiscal year.
Several research firms have recently weighed in on CATB. Wedbush reaffirmed an “outperform” rating and issued a $17.00 price target on shares of Catabasis Pharmaceuticls in a report on Thursday. Zacks Investment Research cut shares of Catabasis Pharmaceuticls from a “buy” rating to a “hold” rating in a report on Monday, July 18th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Catabasis Pharmaceuticls in a report on Wednesday, June 8th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $19.05.
About Catabasis Pharmaceuticls
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Want to see what other hedge funds are holding CATB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catabasis Pharmaceuticls Inc. (NASDAQ:CATB).
Receive News & Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related companies with MarketBeat.com's FREE daily email newsletter.